AnchorDx Medical

Guangzhou AnchorDx Medical Co., Ltd. was established in 2015 on Guangzhou International Bio Island, with research and development centers set up in both China and the United States. The company is committed to the research, production, and sales of early cancer screening and diagnostic products using internationally advanced methylation high-throughput sequencing technology, and also provides corresponding testing services. Dr. Fan Jianbing, the founder, is an international leader in the field of genetic testing. He was listed in the 2021 "Global Top 2% Scientists - Lifetime Scientific Influence" ranking and has nearly 30 years of experience in human genomics, gene chips (Microarrays), and high-throughput sequencing technology development. AnchorDx is a pioneer in China in applying ctDNA methylation high-throughput sequencing technology for early tumor detection. Centering around the two main themes of "a tube of blood" and "a tube of urine," the company develops solutions covering more than 70% of highly prevalent cancers, including lung cancer, breast cancer, digestive system cancers, and urinary system cancers, spanning the entire process of early cancer screening, early diagnosis, recurrence monitoring, and companion diagnostics. In addition, AnchorDx has independently built a big data and artificial intelligence platform focused on early screening, early diagnosis, and treatment of lung cancer. To date, AnchorDx has applied for 75 patents domestically and internationally (with 22 already authorized), all of which are original innovations. Its scientific research achievements have been included in several important international academic journals, laying a significant foundation for global commercialization.